Intellia Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud
LOS ANGELES, Feb. 25, 2025 /PRNewswire/ — The Schall Law Firm, a firm focused on shareholder rights litigation, is urging investors to participate in a class action lawsuit against Intellia Therapeutics, Inc. (“Intellia” or “the Company”) NTLA. The lawsuit claims violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5, as set forth by the U.S. Securities and Exchange Commission.
Investors who bought the Company’s securities from July 30, 2024 to January 8, 2025, inclusive (referred to as the “Class Period”), are encouraged to reach out to the firm before April 14, 2025.
If you experienced a loss as a shareholder, click here to participate.
Additionally, please contact Brian Schall of the Schall Law Firm at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. He can be reached at 310-301-3335 for a free discussion about your rights. More information is available on the firm’s website at www.schallfirm.com or via email at bschall@schallfirm.com.
It’s important to note that the class has not yet been certified. Until certification occurs, investors are not represented by an attorney in this case. Choosing to take no action means you remain an absent class member.
The lawsuit claims that during the class period, the Company issued false and misleading statements to the market. Intellia supposedly misled investors regarding its development and marketing of the drug NTLA-3001, presenting its timelines and future studies as sustainable. However, the Company allegedly faced challenges in delivering doses and maintaining necessary staffing for the drug. These misstatements allegedly led to damages for investors once the true state of the Company’s affairs was revealed.
Investors are invited to join the case to seek potential recovery for their losses.
The Schall Law Firm advocates for investors worldwide and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be viewed as Attorney Advertising in certain jurisdictions based on applicable laws and ethical standards.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia: link
SOURCE: The Schall Law Firm
